Neurological Sciences

, Volume 32, Issue 6, pp 1157–1160 | Cite as

Head tremor secondary to MS resolved with rituximab

  • Chakorn Chansakul
  • Guillermo Moguel-Cobos
  • Roberto BomprezziEmail author
Case Report


We describe the case of a 33-year-old woman who presented with a 2-month history of worsening head tremor. The medical evaluation led to the new diagnosis of MS and the MRI of brain demonstrated prominently active disease. Intravenous rituximab was started according to the HERMES trial, and significant improvement was noted. She has received additional rituximab dosing approximately every 6 months, and at the 2-year follow-up the tremor has not recurred. The resolution of head tremor likely resulted from the complete suppression of MS disease activity, which must have allowed restoration of normal neural circuitry. In agreement with a growing body of evidence that supports early control of MS disease activity to prevent accumulation of fixed disability, this case advocates for aggressive immunological therapy at the onset of tremor in MS patients.


Multiple sclerosis Cerebellar tremor Head tremor Rituximab 


Conflict of interest

Dr. Chansakul reports no disclosures. Dr. Moguel-Cobos reports no disclosures. Dr. Bomprezzi has functioned as principal investigator for clinical trials supported by Genzyme Corporation, Novartis, Serono International, Biogen Idec, Genentech Inc, UCB Pharma Inc. He has received honoraria for consulting with Teva Neuroscience, Biogen Idec, Serono International and Genzyme Corporation.

Supplementary material

Video Legend. A 33-year-old woman with multiple sclerosis presentting with head tremor. Segment 1. The patient before treatment shows a 2.5-Hz head tremor of the ‘yes-yes’type resolved at full rest. Segment 1. The patient before treatment shows a 2.5-Hz head tremor of the ‘yes-yes’ type resolved at full rest. Supplementary material 1 (WMV 8117 kb)


  1. 1.
    Alusi SH, Worthington J, Glickman S, Bain PG (2001) A study of tremor in multiple sclerosis. Brain 124:720–730PubMedCrossRefGoogle Scholar
  2. 2.
    Tranchant C, Bhatia KP, Marsden CD (1995) Movement disorders in multiple sclerosis. Mov Disord 10:418–423PubMedCrossRefGoogle Scholar
  3. 3.
    Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688PubMedCrossRefGoogle Scholar
  4. 4.
    Weiss N, North RB, Ohara S, Lenz FA (2003) Attenuation of cerebellar tremor with implantation of an intrathecal baclofen pump: the role of gamma-aminobutyric acidergic pathways. Case report. J Neurosurg 99:768–771PubMedCrossRefGoogle Scholar
  5. 5.
    Sechi GP, Zuddas M, Piredda M et al (1989) Treatment of cerebellar tremors with carbamazepine: a controlled trial with long term follow up. Neurology 39:1113–1115PubMedGoogle Scholar
  6. 6.
    Koller WC (1984) Pharmacologic trials in the treatment of cerebellar tremor. Arch Neurol 41:280–281PubMedGoogle Scholar
  7. 7.
    Rice GP, Lesaux J, Vandervoort P, Macewan L, Ebers GC (1997) Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry 62:282–284PubMedCrossRefGoogle Scholar
  8. 8.
    Ristori G, Romano S, Visconti A et al (2010) Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 74:839–845PubMedCrossRefGoogle Scholar
  9. 9.
    Deuschl G, Raethjen J, Lindemann M, Krack P (2004) The pathophysiology of tremor. Muscle Nerve 24:716–735CrossRefGoogle Scholar
  10. 10.
    Wilms H, Sievers, Deuschl G et al (1999) Animal models of tremor. Mov Disord 14:557–571PubMedCrossRefGoogle Scholar
  11. 11.
    Comi G, Martinelli V, Rodegher M et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374:1503–1511PubMedCrossRefGoogle Scholar
  12. 12.
    Kappos L, Polman CH, Freedman MS et al (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242–1249PubMedCrossRefGoogle Scholar
  13. 13.
    Franciotta D, Salyetti M, Lolli F, Serafini B, Aloisi F (2008) B cells and multiple sclerosis. Lancet Neurol 7:852–858PubMedCrossRefGoogle Scholar
  14. 14.
    Centonze D, Furlan R, Gasperini C, Salvetti M, Battistini L (2008) Early relapses after the first dose of natalizumab in active multiple sclerosis patients. Mult Scler 14:1137–1138PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Chakorn Chansakul
    • 1
  • Guillermo Moguel-Cobos
    • 1
    • 2
  • Roberto Bomprezzi
    • 1
    Email author
  1. 1.Division of Neurology, Barrow Neurological InstituteSt. Joseph’s Hospital and Medical CenterPhoenixUSA
  2. 2.Muhammad Ali Parkinson Center and Movement Disorders Clinic, Barrow Neurological InstituteSt. Joseph’s Hospital and Medical CenterPhoenixUSA

Personalised recommendations